{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:48:51Z","timestamp":1792900131738,"version":"4.5.0"},"reference-count":31,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Hereditary hemorrhagic telangiectasia (HHT) is an inherited vascular bleeding disorder. The most common symptoms are recurrent, severe nosebleeds that occasionally necessitate intervention by an ENT (Ear, Nose, and Throat) specialist, as well as iron-deficiency anemia. Telangiectasia is typically located in the nasal cavity, lips, tongue, fingertips, and the gastrointestinal mucosa. Arteriovenous malformations (AVMs) are located in internal organs (brain, lungs, liver, etc.). The family history is positive for HHT. The diagnosis is based on the Curacao criteria. The endoglin and activin receptor-like kinase 1 genes (ENG and ACVRL1) are the most common mutation sites, leading to elevated endothelial growth factor (VEGF) levels. Methods: We conducted a retrospective analysis in the Department of Internal Medicine, Division of Hematology, and Center of Expertise for Rare Diseases at the University of Debrecen, spanning the period from 2010 to 2025. Records of patients referred with HHT were reviewed concerning demographic data, clinical presentations, laboratory findings, and treatment approaches. To evaluate management options, epistaxis severity was assessed using the Epistaxis Severity Score (ESS). Results: 48 HHT patients (21 male and 27 female) were included in this retrospective study. Genetic testing was positive in each case, showing mutations in the ENG (HHT1 subgroup) or ACVRL1 (HHT2 subgroup) genes. Most of the patients are followed-up with in our department. ESS was calculated at baseline and 6 months after antiangiogenic treatment by two independent physicians. Detailed computed tomography (CT) was performed in all patients. Seven patients were administered desmopressin, a synthetic analog of antidiuretic hormone (ADH), based on our previous experience in reducing bleeding in von Willebrand disease. Antiangiogenic therapy with thalidomide (50 mg oral tablets) was used in 24 patients, while bevacizumab was administered to 5 patients. Most patients experienced a remarkable decrease in epistaxis severity and a reduction in the need for transfusions (ESS before treatment: HHT1 patients, 4.15 \u00b1 1.91 vs. ESS after treatment, 2.62 \u00b1 0.99; HHT2 patients, 3.79 \u00b1 3.19 vs. 2.02 \u00b1 1.91). Subgroup analysis using paired ESS data showed a significant reduction in ESS in both HHT1 and HHT2 patients (p = 0.003 and p = 0.043, respectively). Bevacizumab further reduced the ESS, but the few cases were not suitable for statistical analysis. Serum iron levels significantly increased after antiangiogenic treatment in the HHT2 group (p = 0.01). Conclusions: HHT is a rare vascular bleeding disorder. Daily nosebleeds impair the patients\u2019 quality of life and sometimes lead to severe transfusion-dependent iron-deficient anemia. Frequent hospitalization places a significant burden on the healthcare system. Thus, we have used treatment options for HHT patients that primarily act by inhibiting VEGF, and these treatment modalities have yielded successful results in our hands.<\/jats:p>","DOI":"10.3390\/jcm14228160","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:55:31Z","timestamp":1763556931000},"page":"8160","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antiangiogenic Treatment of Patients with Hereditary Hemorrhagic Telangiectasia: Experience of a Hungarian Center"],"prefix":"10.3390","volume":"14","author":[{"given":"Bogl\u00e1rka","family":"Brug\u00f3s","sequence":"first","affiliation":[{"name":"Division of Hematology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9la","family":"Csirmaz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Major","sequence":"additional","affiliation":[{"name":"Division of Otorhinolaryngology, Head and Neck Surgery, Markhot Ferenc Teaching Hospital, 3300 Eger, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1483-3703","authenticated-orcid":false,"given":"Zsuzsanna","family":"Bereczky","sequence":"additional","affiliation":[{"name":"Division of Clinical Laboratory Science, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9ka","family":"Gindele","sequence":"additional","affiliation":[{"name":"Division of Clinical Laboratory Science, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1487-5584","authenticated-orcid":false,"given":"G\u00e1bor","family":"Balogh","sequence":"additional","affiliation":[{"name":"Division of Clinical Laboratory Science, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ndor","family":"Kacska","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8168-850X","authenticated-orcid":false,"given":"P\u00e9ter","family":"Sipos","sequence":"additional","affiliation":[{"name":"Faculty of Agricultural and Food Sciences and Environmental Management, Institute of Nutrition, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1rp\u00e1d","family":"Ill\u00e9s","sequence":"additional","affiliation":[{"name":"Division of Hematology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Pfliegler","sequence":"additional","affiliation":[{"name":"Center of Expertise of Rare Diseases, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(03)14696-X","article-title":"Hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease)","volume":"362","author":"Fuchizaki","year":"2003","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.3324\/haematol.2018.193003","article-title":"Hereditary hemorrhagic telangiectasia: Diagnosis and management from the hematologist\u2019s perspective","volume":"103","author":"Kritharis","year":"2018","journal-title":"Haematologica"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","article-title":"Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)","volume":"91","author":"Shovlin","year":"2000","journal-title":"Am. J. Med. Gen."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/00062752-199809000-00005","article-title":"Genetic abnormalities in hereditary hemorrhagic telangiectasia","volume":"5","author":"Marchuk","year":"1998","journal-title":"Curr. Opin. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/s41436-020-0775-8","article-title":"Curacao diagnostic criteria for hereditary hemorrhagic telangiectasia is highly predictive of a pathogenic variant in ENG or ACVRL1 (HHT1 and HHT2)","volume":"22","author":"McDonald","year":"2020","journal-title":"Genet. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/GIM.0b013e3182136d32","article-title":"Hereditary hemorrhagic telangiectasia: An overview of diagnosis, management, and pathogenesis","volume":"13","author":"McDonald","year":"2011","journal-title":"Genet. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejim.2023.08.024","article-title":"New genetic drivers in hemorrhagic hereditary telangiectasia","volume":"119","author":"Cerda","year":"2024","journal-title":"Eur. J. Int. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1556\/650.2019.31380","article-title":"Genetic diagnostics of hereditary hemorrhagic telangiectasia (Osler-Webere-rendu disease)","volume":"160","author":"Major","year":"2019","journal-title":"Orv. Hetil."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Major, T., Bereczky, Z., Gindele, R., Balogh, G., R\u00e1cz, B., Bora, L., K\u00e9zsm\u00e1rki, Z., Br\u00fag\u00f3s, B., and Pfliegler, G. (2021). Current status of clinical and genetic screening of hereditary hemorrhagic telangiectasia families in Hungary. J. Clin. Med., 10.","DOI":"10.3390\/jcm10173774"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/jmg.2004.028712","article-title":"A new locus for hereditary hemorrhagic teleangiecatsia (HHT3) maps to chromosome 5","volume":"42","author":"Cole","year":"2005","journal-title":"J. Med. Genet."},{"key":"ref_11","first-page":"2155","article-title":"A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7","volume":"140","author":"McDonald","year":"2006","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"15040","DOI":"10.1038\/hgv.2015.40","article-title":"Mutations in RASA1 and GDF2 were identified in patients with clinical features of hereditary hemorrhagic telangiectasia","volume":"2","author":"Hernandez","year":"2015","journal-title":"Hum. Genom. Var."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/hematology.2021000281","article-title":"Hereditary hemorrhagic telangiectasia (HHT): A practical guide to management","volume":"1","author":"Hammill","year":"2021","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/M20-1443","article-title":"Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic TelangiecTASIA","volume":"173","author":"Faughnan","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/pmj.79.927.18","article-title":"Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): A view from the 21st century","volume":"79","author":"Begbie","year":"2003","journal-title":"Postgrad. Med. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/00000637-199508000-00017","article-title":"Surgical management of life-threatening epistaxis in Osler-Weber-Rendu disease","volume":"35","author":"Rebeiz","year":"1995","journal-title":"Ann. Plast. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lary.20818","article-title":"An epistaxis severity score for hereditary hemorrhagic telangiectasia","volume":"120","author":"Hoag","year":"2010","journal-title":"Laryngoscope"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/archinte.1990.00040031744026","article-title":"The effect of desmopressin on massive gastrointestinal bleeding in hereditary telangiectasia unresponsive to treatment with cryoprecipitate","volume":"150","author":"Quitt","year":"1990","journal-title":"Arch. Intern. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/pgmj.2006.052118","article-title":"How do you treat bleeding disorders with desmopressin?","volume":"83","author":"Rajpurkar","year":"2007","journal-title":"Postgrad. Med. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1016\/S2352-3026(15)00195-7","article-title":"Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: Results of a non-randomised, single-centre, phase 2 study","volume":"2","author":"Invernizzi","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/0194599817700573","article-title":"Thalidomide for epistaxis in patients with hereditary hemorrhagic telangiectasia: A preliminary study","volume":"157","author":"Fang","year":"2017","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"LBA-3","DOI":"10.1182\/blood-2023-191983","article-title":"PATH-HHT, a double-blind, randomized, placebo-controlled trial in hereditary hemorrhagic telangiectasia, demonstrates that pomalidomide reduces epistaxis and improves quality of life","volume":"142","author":"Kasthuri","year":"2023","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ugur, M., Baysal, M., and Umit, E. (2024). The role of thalidomide and its analogs in the treatment of hereditary hemorrhagic telangiectasia: A systemic review. J. Clin. Med., 13.","DOI":"10.3390\/jcm13185404"},{"key":"ref_24","first-page":"254","article-title":"Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): Regulation of ALK-1\/endoglin pathway in endothelial cells","volume":"92","author":"Ramirez","year":"2007","journal-title":"Thromb. Haemost."},{"key":"ref_25","first-page":"145","article-title":"The use of anti-fibrinolytic agents in patients with HHT: A retrospective survey","volume":"94","author":"Zaffar","year":"2014","journal-title":"Am. Hematol."},{"key":"ref_26","first-page":"2161","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: The InHIBIT-bleed study","volume":"106","author":"Kasthuri","year":"2021","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMc0901421","article-title":"Bevacizumab in hereditary hemorrhagic telangiectasia","volume":"360","author":"Bose","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"E313","DOI":"10.1002\/ajh.24367","article-title":"Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding","volume":"91","author":"Epperla","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/joim.13714","article-title":"Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic telangiectasia: A national randomized multicenter trial","volume":"294","author":"Riviere","year":"2023","journal-title":"J. Int. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4193\/Rhin17.166","article-title":"Intranasal bevacizumab in the treatment of HHT-related epistaxis: A systematic review","volume":"56","author":"Stokes","year":"2018","journal-title":"Rhinology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s42155-021-00270-2","article-title":"Imaging to intervention: A review of what the interventionalist needs to know about hereditary hemorrhagic telangiectasia","volume":"4","author":"Sobrepera","year":"2021","journal-title":"CVIR Endovas."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/8160\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:24:45Z","timestamp":1763558685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/22\/8160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":31,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["jcm14228160"],"URL":"https:\/\/doi.org\/10.3390\/jcm14228160","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]}}}